SCHEMBL1037385

SCHEMBL1037385

Cc1cc(C)c(C(=O)P(CC(=O)c2ccccc2)C(=O)c2c(C)cc(C)cc2C)c(C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.46
MEN1 O00255 7/20 0.46
RAB9A P51151 5/20 0.46
NPC1 O15118 3/20 0.45
MAPT P10636 4/20 0.40
ALDH1A1 P00352 4/20 0.40
HPGD P15428 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
KDM4E B2RXH2 2/20 0.40
MAPK1 P28482 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
CYP3A4 P08684 1/20 0.40
ALOX15 P16050 1/20 0.40
CES1 P23141 1/20 0.40
MGAM O43451 1/20 0.39
AMY1A P0DUB6 1/20 0.39
GAA P10253 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
RECQL P46063 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1034997 0.80 KDM4E (0.40) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL1037678 0.78 LMNA (0.42) KMT2AMEN1RAB9ANPC1SMN1; SMN2
SCHEMBL5507207 0.77 CES2 (0.41) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL11058012 0.77 KMT2A (0.65) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL895436 0.76 KMT2A (0.40) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL50648 0.74 KMT2A (0.56) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL21352315 0.73 KMT2A (0.38) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL1035817 0.72 KDM4E (0.37) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL31070823 0.72 CYP1A2 (0.36) KMT2AMEN1RAB9ANPC1ALDH1A1
Bicarbonate SCHEMBL15643478 0.72 KMT2A (0.54) KMT2AMEN1MAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814891-B1 BISACYLPHOSPHANES AND THEIR USE AS PHOTOINITIATORS; PROCESS FOR PREPARING ACYLPHOSPHANES BASF SE (DE) 2011-01-26 EP disclosed
EP-1814891-B1 BISACYLPHOSPHANES AND THEIR USE AS PHOTOINITIATORS; PROCESS FOR PREPARING ACYLPHOSPHANES BASF SE (DE) 2011-01-26 EP disclosed
US-7687657-B2 Process for preparing acylphosphanes and derivatives thereof CIBA SPECIALITY CHEMICALS CORPORATION (US) 2010-03-30 US disclosed
US-7687657-B2 Process for preparing acylphosphanes and derivatives thereof CIBA SPECIALITY CHEMICALS CORPORATION (US) 2010-03-30 US disclosed
US-7687657-B2 Process for preparing acylphosphanes and derivatives thereof CIBA SPECIALITY CHEMICALS CORPORATION (US) 2010-03-30 US disclosed
US-20080004464-A1 Process for Preparing Acylphosphanes and Derivatives Thereof IGM GROUP B.V. (NL) 2008-01-03 US disclosed
US-20080004464-A1 Process for Preparing Acylphosphanes and Derivatives Thereof IGM GROUP B.V. (NL) 2008-01-03 US disclosed
US-20080004464-A1 Process for Preparing Acylphosphanes and Derivatives Thereof IGM GROUP B.V. (NL) 2008-01-03 US disclosed
EP-1814891-A1 PROCESS FOR PREPARING ACYLPHOSPHANES AND DERIVATIVES THEREOF Ciba Specialty Chemicals Holding Inc. (CH) 2007-08-08 EP disclosed
WO-2006056541-A1 PROCESS FOR PREPARING ACYLPHOSPHANES AND DERIVATIVES THEREOF CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004464-A1 Process for Preparing Acylphosphanes and Derivatives Thereof ME2, ME3, MEP1A KMT2A 490/4885MEN1 46/4885RAB9A 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.